MarketCap
Facebook
X
Telegram
Assertio Holdings Revenue | ASRT
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Assertio Holdings
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 119 M | 125 M | 152 M | 156 M | 111 M | 106 M | 230 M | 312 M | 381 M | 456 M | 343 M | 390 M | 134 M | 90.8 M | 133 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 456 M | 90.8 M | 216 M |
Quarterly Revenue Assertio Holdings
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.93 M | 49.5 M | 29.2 M | 26.5 M | - | 29.2 M | 31.1 M | 32.4 M | - | 35.6 M | 41 M | 42.5 M | - | 34.2 M | 35.1 M | 36.5 M | - | 25.5 M | 25.4 M | 26.8 M | - | 34.6 M | 20.6 M | 20.9 M | - | 55.1 M | 57.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 57.2 M | 9.93 M | 33.3 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Drug manufacturers industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Solid Biosciences
SLDB
|
8.09 M | $ 9.93 | 1.31 % | $ 869 M |  USA |
 |
Sonoma Pharmaceuticals
SNOA
|
19.5 M | $ 1.33 | 0.38 % | $ 2.24 M | USA |
 |
TherapeuticsMD
TXMD
|
3.02 M | $ 2.14 | 0.22 % | $ 24.8 M | USA |
 |
Veru
VERU
|
16.9 M | $ 2.58 | 0.39 % | $ 37.8 M | USA |
 |
Viatris
VTRS
|
14.3 B | $ 16.61 | 0.03 % | $ 19.1 B | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
4.76 M | - | 0.86 % | $ 117 M | USA |
 |
Agile Therapeutics
AGRX
|
19.6 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
80.8 M | - | - | $ 142 M | USA |
 |
Catalent
CTLT
|
4.38 B | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
2.03 M | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
317 M | - | -39.89 % | $ 27.7 M | USA |
 |
Lannett Company
LCI
|
341 M | - | 1.15 % | $ 7.11 M | USA |
 |
OptiNose
OPTN
|
78.2 M | - | - | $ 1.08 B | USA |
 |
PetIQ
PETQ
|
1.1 B | - | 1.64 % | $ 400 M | USA |
 |
Radius Health
RDUS
|
230 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
94.6 M | - | -4.76 % | $ 65.3 M | USA |
 |
Emergent BioSolutions
EBS
|
743 M | $ 6.0 | 0.08 % | $ 321 M | USA |
 |
Endo International plc
ENDP
|
2.01 B | - | - | $ 28.9 M |  Irlanda |
 |
Relmada Therapeutics
RLMD
|
5.13 K | $ 4.25 | 1.37 % | $ 168 M | USA |
 |
Bausch Health Companies
BHC
|
10.3 B | $ 6.43 | 0.31 % | $ 2.38 B |  Canada |
 |
PLx Pharma
PLXP
|
8.21 M | - | -27.8 % | $ 2.56 M | USA |
 |
HEXO Corp.
HEXO
|
191 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
874 K | - | -0.1 % | $ 2.03 B |  Schweden |
 |
Athenex
ATNX
|
103 M | - | -23.39 % | $ 1.76 M | USA |
 |
China Pharma Holdings
CPHI
|
4.14 M | $ 0.84 | 2.56 % | $ 3.6 M |  China |
 |
Cumberland Pharmaceuticals
CPIX
|
13.7 M | $ 6.62 | 0.29 % | $ 98.3 M | USA |
 |
Cronos Group
CRON
|
147 M | $ 3.19 | 0.62 % | $ 1.22 B | Canada |
 |
Evolus
EOLS
|
297 M | $ 8.88 | 2.76 % | $ 572 M | USA |
 |
Harrow Health
HROW
|
272 M | $ 37.85 | 0.73 % | $ 1.39 B | USA |
 |
Sundial Growers
SNDL
|
946 M | $ 1.44 | 0.35 % | $ 372 M | Canada |
 |
Canopy Growth Corporation
CGC
|
285 M | $ 0.97 | 1.73 % | $ 289 M | Canada |
 |
OrganiGram Holdings
OGI
|
160 M | $ 1.12 | 0.42 % | $ 107 M | Canada |
 |
Aurora Cannabis
ACB
|
175 M | $ 3.87 | 1.54 % | $ 212 M | Canada |
 |
Organogenesis Holdings
ORGO
|
564 M | $ 1.6 | 4.27 % | $ 203 M | USA |
 |
Pacira BioSciences
PCRX
|
726 M | $ 25.87 | 0.08 % | $ 1.15 B | USA |
 |
Perrigo Company plc
PRGO
|
4.25 B | $ 14.58 | 4.56 % | $ 2.02 B | USA |
 |
Rockwell Medical
RMTI
|
69.3 M | $ 8.06 | 0.94 % | $ 290 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
194 M | - | - | $ 754 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
28 K | - | 7.5 % | $ 6.35 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
169 M | - | - | $ 2.06 B |  France |
 |
Evoke Pharma
EVOK
|
10.2 M | - | - | $ 36.6 M | USA |
 |
Jupiter Wellness
JUPW
|
2.12 M | - | - | $ 33.6 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
925 K | - | - | $ 193 M | Canada |
 |
ProPhase Labs
PRPH
|
4.34 M | - | - | $ 5.07 M | USA |
 |
SCYNEXIS
SCYX
|
20.6 M | $ 5.15 | 0.75 % | $ 257 M | USA |
 |
Tilray
TLRY
|
821 M | $ 4.3 | 0.22 % | $ 3.83 B | Canada |
 |
cbdMD
YCBD
|
19.2 M | $ 0.5 | 5.07 % | $ 2.01 M | USA |
 |
Zomedica Corp.
ZOM
|
32 M | - | -0.21 % | $ 98 M | USA |